Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CSNK1E | P49674 | 4/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.41 |
| ▸ | RAF1 | P04049 | 3/20 | 0.40 |
| ▸ | BRAF | P15056 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | C1R | P00736 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CSNK1G3 | Q9Y6M4 | 1/20 | 0.39 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | DDX3X | O00571 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2931275 | 0.96 | ABL1 (0.47) | ABL1ALDH1A1SMN1; SMN2CSNK1ECSNK1D | |
| SCHEMBL14693551 | 0.89 | MAPT (0.53) | ABL1ALDH1A1SMN1; SMN2TP53NPC1 | |
| SCHEMBL2929849 | 0.86 | RAF1 (0.51) | ABL1ALDH1A1RAF1BRAFNPC1 | |
| SCHEMBL14693664 | 0.81 | DDX3X (0.39) | ABL1ALDH1A1SMN1; SMN2RAF1BRAF | |
| SCHEMBL2933012 | 0.81 | RAF1 (0.47) | ALDH1A1RAF1BRAFNPC1RAB9A | |
| SCHEMBL14693564 | 0.80 | KDR (0.41) | ABL1CSNK1DTP53MAPTDDX3X | |
| SCHEMBL2932514 | 0.80 | RAF1 (0.48) | ALDH1A1RAF1BRAFNPC1RAB9A | |
| SCHEMBL2930334 | 0.80 | SMN1; SMN2 (0.50) | ABL1ALDH1A1SMN1; SMN2CSNK1ECSNK1D | |
| SCHEMBL2928418 | 0.79 | RAF1 (0.48) | RAF1BRAFDDX3X | |
| SCHEMBL2934497 | 0.78 | KDR (0.44) | ALDH1A1RAF1BRAFMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377983-B2 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | TRANSTECH PHARMA, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-7820821-B2 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | TRANSTECH PHARMA, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-20100152170-A1 | Benzazole Derivatives, Compositions, And Methods Of Use As Aurora Kinase Inhibitors | TRANSTECH PHARMA, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20070219235-A1 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | VTVX HOLDINGS I LLC | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152170-A1 | Benzazole Derivatives, Compositions, And Methods Of Use As Aurora Kinase Inhibitors | AURKC, AURKA, AURKB | ABL1 70/4885ALDH1A1 3036/4885SMN1; SMN2 4734/4885 |
| US-20070219235-A1 | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | AURKC, AURKA, AURKB | ABL1 70/4885ALDH1A1 3036/4885SMN1; SMN2 4734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.